Oramed Pharmaceuticals Inc. acquisition of Oratech

Oramed Pharmaceuticals Inc. completed its acquisition of Oratech on 2026-03-25, according to the Form 8-K Oramed Pharmaceuticals Inc. filed with the SEC on 2026-03-31. The filing states a price of $200 million.

Want the whole picture on Oramed Pharmaceuticals Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Oramed Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Oramed Pharmaceuticals Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

What the filing says

On March 25, 2026, Lifeward completed its acquisition of Oratech in accordance with the terms of the Share Purchase Agreement.

The price, in the filing's words

Pursuant to the Share Purchase Agreement, Lifeward agreed to acquire all of the outstanding equity interests in Oratech from the Company in consideration for (A) Lifeward issuing to the Company a number of ordinary shares, no par value per share, of Lifeward ("Lifeward Ordinary Shares"), and pre-funded warrants (the "Pre-Funded Warrants") to purchase the number of Lifeward Ordinary Shares equal to up to 49.99% of Lifeward's fully diluted equity capitalization, (B) Lifeward issuing to the Company warrants (the "Share Purchase Warrants") to purchase Lifeward Ordinary Shares, and (C) certain ongoing revenue-based payments (the "Revenue Sharing Payments") equal to 4% of the Net Revenue (as defin

More from the filing

Entry Into a Material Definitive Agreement.

Closing of Share Purchase Agreement As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on January 14, 2026 (the "Prior 8-K"), on January 12, 2026, Oramed Pharmaceuticals Inc. (the "Company") entered into that certain Share Purchase Agreement ("Share Purchase Agreement"), by and among the Company, Lifeward Ltd. ("Lifeward") and Oratech Pharma, Inc., the Company's wholly-owned subsidiary ("Oratech").

Pursuant to the Share Purchase Agreement, Lifeward agreed to acquire all of the outstanding equity interests in Oratech from the Company in consideration for (A) Lifeward issuing to the Company a number of ordinary shares, no par value per share, of Lifeward ("Lifeward Ordinary Shares"), and pre-funded warrants (the "Pre-Funded Warrants") to purchase the number of Lifeward Ordinary Shares equal to up to 49.99% of Lifeward's fully diluted equity capitalization, (B) Lifeward issuing to the Company warrants (the "Share Purchase Warrants") to purchase Lifeward Ordinary Shares, and (C) certain ongo

Quoted from Oramed Pharmaceuticals Inc.'s Form 8-K.

This is the only completed acquisition Oramed Pharmaceuticals Inc. reported under Item 2.01 in the last twelve months.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.

Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.

All recent acquisitions